9 Meters Biopharma, Inc. (NMTR) News

9 Meters Biopharma, Inc. (NMTR): $0.22

-0.04 (-13.77%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NMTR to Watchlist
Sign Up

Industry: Biotech


Ranked

of 399

in industry

Filter NMTR News Items

NMTR News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

NMTR News Highlights

  • For NMTR, its 30 day story count is now at 2.
  • Over the past 1 day, the trend for NMTR's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • NC and RARE are the most mentioned tickers in articles about NMTR.

Latest NMTR News From Around the Web

Below are the latest news stories about 9 Meters Biopharma Inc that investors may wish to consider to help them evaluate NMTR as an investment opportunity.

9 Meters Biopharma to Present at the 2022 BIO CEO & Investor Conference

RALEIGH, NC / ACCESSWIRE / February 9, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases announced today that John Temperato, President & Chief Executive Officer of 9 Meters Biopharma, Inc.

Yahoo | February 9, 2022

Paradigm, Strategies in Wealth Management, LLC Buys iShares iBonds Dec 2023 Term Corporate ETF, ...

Investment company Paradigm, Strategies in Wealth Management, LLC (Current Portfolio) buys iShares iBonds Dec 2023 Term Corporate ETF, iShares iBonds Dec 2023 Term Muni Bond ETF, Costco Wholesale Corp, Prologis Inc, Altria Group Inc, sells iShares iBonds Dec 2021 Term Corporate ETF, iShares iBonds Dec 2021 Term Muni Bond ETF, Wells Fargo, Invesco Preferred ETF, Schwab International Equity ETF during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Paradi

Yahoo | February 8, 2022

9 Meters Biopharma Announces Allowance of Patent for NM-102 in Combination with Immune Checkpoint Inhibitors

RALEIGH, NC / ACCESSWIRE / January 24, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced today that the Company has received notice from the United States Patent and Trademark Office (USPTO) that U.

Yahoo | January 24, 2022

Raleigh public company adds former Biogen exec to C-suite

A relatively new biopharmaceutical company in Raleigh has added a new name to its C-suite. 9 Meters Biopharma (Nasdaq: NMTR) has appointed Bethany Sensenig to be chief financial officer. Sensenig is joining the clinical-stage company, which is focused on developing drugs for rare digestive diseases, less than two years after it was formed via a three-way merger that involved a Triangle drugmaker.

Yahoo | January 21, 2022

9 Meters Biopharma Appoints Bethany Sensenig as Chief Financial Officer

Formerly served as VP of Finance and Commercial Operations at Biogen with 20+ years of business and strategic financial leadership experienceRALEIGH, NC / ACCESSWIRE / January 18, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases announced today the Company has appointed Bethany Sensenig, MBA, CMA, as Chief Financial Officer.

Yahoo | January 18, 2022

9 Meters Biopharma, Inc. to Participate in the following Virtual January Investor Conferences

RALEIGH, NC / ACCESSWIRE / January 4, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR) (the "Company"), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, today announced that the Company's CEO, John Temperato along with other management team members will participate in the following conferences in January and invites investors to participate in virtual one-on-one meetings.

Yahoo | January 4, 2022

9 Meters Biopharma Appoints Sarah Liu as Chief Commercial Officer and Al Medwar as Senior Vice President of Investor Relations & Corporate Communications

RALEIGH, NC / ACCESSWIRE / January 3, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR),a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, announced today the Company has appointed Sarah Liu, MBA, as Chief Commercial Officer and Al Medwar, MBA, as Senior Vice President, Investor Relations & Corporate Communications.

Yahoo | January 3, 2022

2 “Strong Buy” Penny Stocks That Can Deliver Over 200% Gains Next Year

Every class of stocks has its promoters and detractors, but few generate such extreme opinions among investors as the penny stocks. The reality is, they’re a class of assets that offer some unique opportunities combined with a higher risk profile.  The ‘pennies’ are stocks selling at ultra-low prices per share. Originally, they were priced for just a few pennies, but today this class of stocks is generally valued at less than $5 per share. Such low share prices generally happen for clear reasons, and those reasons usually revolve around something fundamentally wrong with the issuing company. But not always.

Michael Marcus on TipRanks | December 16, 2021

9 Meters Biopharma, Inc. Awards Unrestricted Educational Grant Funding to Carol Rees Parrish, M.S., RDN, for Short Bowel Syndrome Education

RALEIGH, NC / ACCESSWIRE / December 15, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR) (the "Company"), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases by studying unique GI biology, today announced the company has awarded an unrestricted educational grant to Carol Rees Parrish, M.

Yahoo | December 15, 2021

Down 20.5% in 4 Weeks, Here's Why You Should You Buy the Dip in 9 Meters Biopharma, Inc. (NMTR)

The heavy selling pressure might have exhausted for 9 Meters Biopharma, Inc. (NMTR) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Yahoo | November 18, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4554 seconds.